- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04139486
adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion (VECTOR)
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four ... passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi (25-28). This could, be related to worst clinical outcome at 3 months. VECTOR asks a relevant question: Do the invetigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sudden occlusion of an intracranial artery by a thrombus represents the initial and pivotal event of large vessel occlusion acute ischemic stroke (AIS). The primary goal of AIS treatment is to re-open this artery with intravenous tissue-type plasminogen activator infusion (IV t-PA) and/or endovascular therapy (EVT). Thrombus characterization could be useful to predict AIS etiology, IV t-PA response and to adapt the device or technique for EVT. Especially, approaching the red blood cell (RBC) content of the thrombus would be helpful to plan a treatment strategy or identify specific EVT approaches in order to maximize the rate of early successful reperfusion .
The susceptibility vessel sign (SVS) on T2*-MRI sequence is defined as a hypo-intense signal exceeding the diameter of the contralateral artery located at the site of the thrombus. Several studies have demonstrated SVS to be a negative predictor of early reperfusion after IV t-PA and an incentive to EVT . Two studies identified a correlation between the SVS and the thrombus composition (specifically the RBC composition). In the ASTER trial, the presence of SVS impacted the success rate of the EVT strategy. In the SVS (+) sub-population of this study, compared to contact aspiration (CA), patients treated with stent retrievers achieved higher rates of complete reperfusion within fewer passes, which translated into a better functional outcome. In the absence of SVS, no differences were observed between the two techniques. Furthermore; based on the ASTER and THRACE trial populations treated with stent retriever as a first line strategy, a higher rate of favorable clinical outcome at 3 months in SVS (+) patients was recently found . Hence, that differences in terms of reperfusion results are thought to be related to different clot compositions between SVS + and SVS - occlusions.
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi. This could, be related to worst clinical outcome at 3 months.
VECTOR asks a relevant question: Do the investigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots? The hypothesis in the VECTOR trial is that the Embotrap II or III, thanks to its dedicated design will help to the stabilization of friable clots and allow better retrieving of SVS + thrombi in a lower number of passes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amiens, France
- CHU Amiens-Picardie
-
Angers, France
- CH Angers
-
Bayonne, France, 64109
- CH Cote Basque
-
Bordeaux, France
- Hôpital Pellegrin - CHU BORDEAUX
-
Brest, France
- CHRU Brest
-
Le Kremlin-Bicêtre, France
- Hôpital Bicêtre
-
Lille, France
- Hôpital Roger Salengro - CHR Lille
-
Limoges, France
- Chu Limoges
-
Lyon, France
- Hospices Civils Lyon
-
Marseille, France, 13385
- CHU Marseille - Hôpital la Timone
-
Montpellier, France
- CHU Gui de Chauliac
-
Nancy, France
- Chu Nancy
-
Nantes, France
- CHU de Nantes
-
Paris, France, 75019
- Fondation Ophtalmologique Adolphe de Rothschild
-
Paris, France
- La Pitié Salpêtrière
-
Paris, France
- Hôpital Ste Anne
-
Pau, France, 64000
- CH Pau
-
Reims, France
- Hôpital Maison Blanche - CHU Reims
-
Rennes, France
- Hopital Pontchaillou - CHU Rennes
-
Strasbourg, France, 67000
- CHU Strasbourg
-
Suresnes, France
- Hopital Foch
-
Tours, France
- Hôpital Bretonneau - CHU Tours
-
Vannes, France
- CH Bretagne Atlantique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 and older (i.e., candidates must have had their 18th birthday)
- Puncture carried out within 24 hours of first symptoms
- Suitable 1.5T MRI T2 * Gradient echo that shows a clear susceptibility vessel sign facing the occlusion
- Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation, M1 or proximal M2)
- Patient or trustworthy person informed about the study and having orally consented to participation in the study. If the patient is unable to receive information and no trustworthy person can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the investigator, in compliance with the French laws
- With or without intravenous thrombolysis
Exclusion Criteria:
- Absence of large vessel occlusion on non-invasive imaging
- Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory
- Suspected pregnancy; if, in a woman is of child-bearing potential, a urine or serum beta HCG test is positive
- Severe contrast medium allergy or absolute contraindication to use of iodinated products
- Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic
- Patient has severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient
- Acute ischemic stroke involving posterior circulation (vertebro-basilar occlusion)
- Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment
- Pregnant or breast-feeding women
- Patient benefiting from a legal protection
- Non-membership of a national insurance scheme
- Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person
- Patient with modified Rankin score > 3 before qualifying stroke
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: combined EMBOTRAP II or III and Contact Aspiration
|
refer to title
|
Active Comparator: Contact Aspiration alone
|
refer to title
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of near to complete reperfusion after 3 passes of the device defined by a modified treatment in cerebral infarction (eTICI) score of 2c/3
Time Frame: At Day 0 immediately after 3 passes
|
Preliminary data suggested in case of SVS+ occlusions a superiority of the first line SR strategy in terms of eTICI2c/3 after 3 passes compared to first line CA alone.The first pass (FPE) is an ambitious technical endpoint defined as a successful reperfusion obtained after the first pass that has been recently associated with an increased probability of favorable clinical outcome, a reduced mortality rate and procedural adverse events.However, this constitutes a "very technical" endpoint and the external validity in daily practice would be reduced compared to the three passes cut-off.Even if a FPE eTICI 2b, 2c or 3 has shown better clinical outcome compared to a final eTICI 2b, 2c or 3,there is no study that has proved the better clinical outcome when compared FPE eTICI 2b,2c or 3 to three passes eTICI 2b,2c or 3.Last, there was no preliminary data that suggests in case of SVS+ occlusions, a superiority of the first pass SR strategy in terms eTICI2c/3 compared to first pass CA alone.
|
At Day 0 immediately after 3 passes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Near to complete first-pass effect
Time Frame: Day 0 immediately after first pass
|
Defined as a eTICI 2c/3 after first pass device
|
Day 0 immediately after first pass
|
Complete first-pass effect
Time Frame: Day 0 immediately after first pass
|
Defined as a eTICI 3 after first pass device
|
Day 0 immediately after first pass
|
Complete reperfusion
Time Frame: Day 0 immediately after three passes
|
Defined as eTICI 3 after three passes
|
Day 0 immediately after three passes
|
Final near to complete reperfusion
Time Frame: Day 0 at the end of the intervention
|
Defined as eTICI 2c/3 final
|
Day 0 at the end of the intervention
|
Final complete reperfusion
Time Frame: Day 0 at the end of the intervention
|
Defined as eTICI 3
|
Day 0 at the end of the intervention
|
Time to achieve eTICI 2c or better revascularization
Time Frame: Day 0
|
Time to achieve eTICI 2c or better revascularization
|
Day 0
|
Time between groin puncture to clot contact
Time Frame: Day 0
|
Time between groin puncture to clot contact
|
Day 0
|
Rate of functional independence
Time Frame: At 90days
|
Defined as a modified Rankin scale (mRS) 0-2
|
At 90days
|
Rate of excellent functional outcome
Time Frame: At 90days
|
Defined as a mRS 0-1
|
At 90days
|
The distribution of mRs scores
Time Frame: At 90days
|
Combining scores of 9 and 10
|
At 90days
|
Change in NIHSS from baseline to 24 hours
Time Frame: Baseline and 24hours
|
Change in NIHSS
|
Baseline and 24hours
|
Rate of symptomatic and asymptomatic intracerebral hemorrhage
Time Frame: At 24hrs
|
Assessment of symptomatic and asymptomatic intracerebral hemorrhage at MRI or CT scan 24h after thrombectomy
|
At 24hrs
|
Rate of parenchymal hematoma type 1 and 2
Time Frame: At 24hrs
|
Assessment of parenchymal hematoma type 1 and 2
|
At 24hrs
|
Rate of all-cause mortality at 90 days
Time Frame: At 90days
|
Assessment of all-cause mortality at 90 days
|
At 90days
|
Rate of periprocedural complications
Time Frame: At 90days
|
Occurrence of emboli to new territory, vasospasm, dissection, perforation and subarachnoid hemorrhage
|
At 90days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Romain Bourcier, CHU Nantes
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC19_0174
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Thrombosis
-
Jan Stam, MD, PhDDutch Heart FoundationTerminatedSinus Thrombosis, IntracranialNetherlands, France, China, Portugal, Canada, Switzerland
-
Ji Xunming,MD,PhDRecruitingCerebral Venous Sinus ThrombosisChina
-
Capital Medical UniversityThe First Affiliated Hospital of Zhengzhou University; Guizhou Provincial People... and other collaboratorsCompletedCerebral Vein Thrombosis | Cerebral Venous Sinus ThrombosisChina
-
Capital Medical UniversityUnknownCerebral Venous Sinus Thrombosis | BatroxobinChina
-
Boehringer IngelheimCompletedThromboembolismSpain, Germany, India, Italy, Netherlands, Portugal, France, Poland, Russian Federation
-
Assiut UniversityNot yet recruitingCerebral Vein Thrombosis
-
Medical University of South CarolinaRecruitingStroke | Thromboses, Intracranial | Aneurysm, BrainUnited States, Spain, Korea, Republic of, Germany, Switzerland, Canada, Argentina, Japan, Portugal, Uruguay, Egypt
-
Capital Medical UniversityRecruitingVenous Sinus Thrombosis, CranialChina
-
University Hospital, AkershusUniversity of Oslo; Oslo University Hospital; Rigshospitalet, Denmark; University... and other collaboratorsRecruitingCerebral Vein Thrombosis | Cerebral Venous Sinus ThrombosisNorway
-
Capital Medical UniversityBeijing Municipal Science & Technology CommissionNot yet recruitingCerebral Venous Sinus Thrombosis | Deep Cerebral Vein Thrombosis | Cortical Vein Thrombosis
Clinical Trials on combined EMBOTRAP II or III and Contact Aspiration
-
Duke UniversityActive, not recruitingMental Disorder | Behavior Problem | Emotional ProblemUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingOndine Syndrome | Congenital Central Hypoventilation Syndrome (CCHS)France
-
Fudan UniversityNot yet recruiting
-
Sun Yat-sen UniversityRecruiting
-
Postgraduate Institute of Medical Education and...Unknown
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | AML Stage, AdultChina
-
Schering-PloughCompleted
-
University Hospital, RouenFederation Francophone de Cancerologie DigestiveRecruiting
-
CelgeneCompletedHealthy VolunteersUnited States
-
Centre Hospitalier Universitaire de NiceNot yet recruitingInfections Joint ProstheticFrance